Loading…
Evaluation of nine serological rapid tests for the detection of SARS-CoV-2
Objective. To evaluate the operative capacity of nine serological rapid tests to detect the IgM/IgG antibodies response in serum from patients with SARS-CoV-2 in different clinical stages. Methods. A cross-sectional study of serological rapid tests was designed to compare the performance of the eval...
Saved in:
Published in: | Revista panamericana de salud pública 2020-12, Vol.44 (149), p.1-9 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3 |
container_end_page | 9 |
container_issue | 149 |
container_start_page | 1 |
container_title | Revista panamericana de salud pública |
container_volume | 44 |
creator | Mercado, Marcela Malagón-Rojas, Jeadran Delgado, Gabriela Rubio, Vivian Vanesa Muñoz Galindo, Lida Parra Barrera, Eliana L. Gaviria, Paula Zabaleta, Gabriela Alarcon, Zonia Arévalo, Adriana Cifuentes, Helly Casallas Estrada, Kelly Puerto, Gloria Herrera Sepúlveda, María T. Rodríguez, Helena Galindo, Marisol Ospina Ramírez, Martha Lucía |
description | Objective.
To evaluate the operative capacity of nine serological rapid tests to detect the IgM/IgG antibodies response in serum from patients with SARS-CoV-2 in different clinical stages.
Methods.
A cross-sectional study of serological rapid tests was designed to compare the performance of the evaluated immunochromatographic tests for the diagnosis of SARS-CoV-2. A total of 293 samples was used, including negatives, asymptomatic, and symptomatic serum samples.
Results.
The sensitivity of the evaluated tests was low and moderate in the groups of asymptomatic serum samples and the group of serums coming from patients with less than 11 days since the onset of the symptoms. The specificity for the anti-SARS-CoV-2 antibodies tests ranged between 86.5%-99% for IgM and 86.5%-99.5% for IgG. The sensitivity and the likelihood ratio were different according to the study groups. The usefulness of these tests is restricted to symptomatic patients and their sensitivity is greater than 85% after 11 days from the appearance of symptoms.
Conclusions.
Serological tests are not an adequate strategy for the identification of asymptomatic and pre-symptomatic patients. Serological rapid tests for the detection of specific anti-SARS-CoV-2 antibodies can be used as a diagnostic aid, but diagnosis must be confirmed by RT-PCR. Rapid tests should be reserved for patients with symptoms lasting more than 11 days. |
doi_str_mv | 10.26633/RPSP.2020.149 |
format | article |
fullrecord | <record><control><sourceid>pubmedcentral_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_470c6cc78890490a92100f3454bd3185</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_470c6cc78890490a92100f3454bd3185</doaj_id><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_7734239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3</originalsourceid><addsrcrecordid>eNpVkV1LwzAUhosoOKe3XvcPdJ58NE1uhDGmTgTHpt6GJE23jq4ZSTbw39tuKuzqvLyH97l5kuQewQgzRsjDYr6cjzBgGCEqLpIBYhyynFB-2eWuzqjg4jq5CWEDgBEjaJC8Tg-q2atYuzZ1VdrWrU2D9a5xq9qoJvVqV5dptCGGtHI-jWubljZa87dYjhfLbOK-MnybXFWqCfbu9w6Tz6fpx-Qle3t_nk3Gb5khBGLGhNWcaa2NpkDBVIKCpQYbyI3QLEe6awgGQYy1fcIUAVQacQpaUE2GyezELZ3ayJ2vt8p_S6dqeSycX0nlY20aK2kBhhlTcC6AClAC9yhCc6pLgnjesR5PrN1eb21pbBu9as6g55-2XsuVO8iiIBQT0QFGJ4DxLgRvq_8tAnnUInststciOy3kBx5Qf3U</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evaluation of nine serological rapid tests for the detection of SARS-CoV-2</title><source>PubMed Central(OpenAccess)</source><creator>Mercado, Marcela ; Malagón-Rojas, Jeadran ; Delgado, Gabriela ; Rubio, Vivian Vanesa ; Muñoz Galindo, Lida ; Parra Barrera, Eliana L. ; Gaviria, Paula ; Zabaleta, Gabriela ; Alarcon, Zonia ; Arévalo, Adriana ; Cifuentes, Helly Casallas ; Estrada, Kelly ; Puerto, Gloria ; Herrera Sepúlveda, María T. ; Rodríguez, Helena ; Galindo, Marisol ; Ospina Ramírez, Martha Lucía</creator><creatorcontrib>Mercado, Marcela ; Malagón-Rojas, Jeadran ; Delgado, Gabriela ; Rubio, Vivian Vanesa ; Muñoz Galindo, Lida ; Parra Barrera, Eliana L. ; Gaviria, Paula ; Zabaleta, Gabriela ; Alarcon, Zonia ; Arévalo, Adriana ; Cifuentes, Helly Casallas ; Estrada, Kelly ; Puerto, Gloria ; Herrera Sepúlveda, María T. ; Rodríguez, Helena ; Galindo, Marisol ; Ospina Ramírez, Martha Lucía</creatorcontrib><description>Objective.
To evaluate the operative capacity of nine serological rapid tests to detect the IgM/IgG antibodies response in serum from patients with SARS-CoV-2 in different clinical stages.
Methods.
A cross-sectional study of serological rapid tests was designed to compare the performance of the evaluated immunochromatographic tests for the diagnosis of SARS-CoV-2. A total of 293 samples was used, including negatives, asymptomatic, and symptomatic serum samples.
Results.
The sensitivity of the evaluated tests was low and moderate in the groups of asymptomatic serum samples and the group of serums coming from patients with less than 11 days since the onset of the symptoms. The specificity for the anti-SARS-CoV-2 antibodies tests ranged between 86.5%-99% for IgM and 86.5%-99.5% for IgG. The sensitivity and the likelihood ratio were different according to the study groups. The usefulness of these tests is restricted to symptomatic patients and their sensitivity is greater than 85% after 11 days from the appearance of symptoms.
Conclusions.
Serological tests are not an adequate strategy for the identification of asymptomatic and pre-symptomatic patients. Serological rapid tests for the detection of specific anti-SARS-CoV-2 antibodies can be used as a diagnostic aid, but diagnosis must be confirmed by RT-PCR. Rapid tests should be reserved for patients with symptoms lasting more than 11 days.</description><identifier>ISSN: 1020-4989</identifier><identifier>EISSN: 1680-5348</identifier><identifier>DOI: 10.26633/RPSP.2020.149</identifier><language>eng</language><publisher>Organización Panamericana de la Salud</publisher><subject>betacoronavirus ; colombia ; coronavirus infections ; diagnostics ; Original Research ; serologic tests</subject><ispartof>Revista panamericana de salud pública, 2020-12, Vol.44 (149), p.1-9</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3</citedby><cites>FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734239/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734239/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Mercado, Marcela</creatorcontrib><creatorcontrib>Malagón-Rojas, Jeadran</creatorcontrib><creatorcontrib>Delgado, Gabriela</creatorcontrib><creatorcontrib>Rubio, Vivian Vanesa</creatorcontrib><creatorcontrib>Muñoz Galindo, Lida</creatorcontrib><creatorcontrib>Parra Barrera, Eliana L.</creatorcontrib><creatorcontrib>Gaviria, Paula</creatorcontrib><creatorcontrib>Zabaleta, Gabriela</creatorcontrib><creatorcontrib>Alarcon, Zonia</creatorcontrib><creatorcontrib>Arévalo, Adriana</creatorcontrib><creatorcontrib>Cifuentes, Helly Casallas</creatorcontrib><creatorcontrib>Estrada, Kelly</creatorcontrib><creatorcontrib>Puerto, Gloria</creatorcontrib><creatorcontrib>Herrera Sepúlveda, María T.</creatorcontrib><creatorcontrib>Rodríguez, Helena</creatorcontrib><creatorcontrib>Galindo, Marisol</creatorcontrib><creatorcontrib>Ospina Ramírez, Martha Lucía</creatorcontrib><title>Evaluation of nine serological rapid tests for the detection of SARS-CoV-2</title><title>Revista panamericana de salud pública</title><description>Objective.
To evaluate the operative capacity of nine serological rapid tests to detect the IgM/IgG antibodies response in serum from patients with SARS-CoV-2 in different clinical stages.
Methods.
A cross-sectional study of serological rapid tests was designed to compare the performance of the evaluated immunochromatographic tests for the diagnosis of SARS-CoV-2. A total of 293 samples was used, including negatives, asymptomatic, and symptomatic serum samples.
Results.
The sensitivity of the evaluated tests was low and moderate in the groups of asymptomatic serum samples and the group of serums coming from patients with less than 11 days since the onset of the symptoms. The specificity for the anti-SARS-CoV-2 antibodies tests ranged between 86.5%-99% for IgM and 86.5%-99.5% for IgG. The sensitivity and the likelihood ratio were different according to the study groups. The usefulness of these tests is restricted to symptomatic patients and their sensitivity is greater than 85% after 11 days from the appearance of symptoms.
Conclusions.
Serological tests are not an adequate strategy for the identification of asymptomatic and pre-symptomatic patients. Serological rapid tests for the detection of specific anti-SARS-CoV-2 antibodies can be used as a diagnostic aid, but diagnosis must be confirmed by RT-PCR. Rapid tests should be reserved for patients with symptoms lasting more than 11 days.</description><subject>betacoronavirus</subject><subject>colombia</subject><subject>coronavirus infections</subject><subject>diagnostics</subject><subject>Original Research</subject><subject>serologic tests</subject><issn>1020-4989</issn><issn>1680-5348</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkV1LwzAUhosoOKe3XvcPdJ58NE1uhDGmTgTHpt6GJE23jq4ZSTbw39tuKuzqvLyH97l5kuQewQgzRsjDYr6cjzBgGCEqLpIBYhyynFB-2eWuzqjg4jq5CWEDgBEjaJC8Tg-q2atYuzZ1VdrWrU2D9a5xq9qoJvVqV5dptCGGtHI-jWubljZa87dYjhfLbOK-MnybXFWqCfbu9w6Tz6fpx-Qle3t_nk3Gb5khBGLGhNWcaa2NpkDBVIKCpQYbyI3QLEe6awgGQYy1fcIUAVQacQpaUE2GyezELZ3ayJ2vt8p_S6dqeSycX0nlY20aK2kBhhlTcC6AClAC9yhCc6pLgnjesR5PrN1eb21pbBu9as6g55-2XsuVO8iiIBQT0QFGJ4DxLgRvq_8tAnnUInststciOy3kBx5Qf3U</recordid><startdate>20201214</startdate><enddate>20201214</enddate><creator>Mercado, Marcela</creator><creator>Malagón-Rojas, Jeadran</creator><creator>Delgado, Gabriela</creator><creator>Rubio, Vivian Vanesa</creator><creator>Muñoz Galindo, Lida</creator><creator>Parra Barrera, Eliana L.</creator><creator>Gaviria, Paula</creator><creator>Zabaleta, Gabriela</creator><creator>Alarcon, Zonia</creator><creator>Arévalo, Adriana</creator><creator>Cifuentes, Helly Casallas</creator><creator>Estrada, Kelly</creator><creator>Puerto, Gloria</creator><creator>Herrera Sepúlveda, María T.</creator><creator>Rodríguez, Helena</creator><creator>Galindo, Marisol</creator><creator>Ospina Ramírez, Martha Lucía</creator><general>Organización Panamericana de la Salud</general><general>Pan American Health Organization</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20201214</creationdate><title>Evaluation of nine serological rapid tests for the detection of SARS-CoV-2</title><author>Mercado, Marcela ; Malagón-Rojas, Jeadran ; Delgado, Gabriela ; Rubio, Vivian Vanesa ; Muñoz Galindo, Lida ; Parra Barrera, Eliana L. ; Gaviria, Paula ; Zabaleta, Gabriela ; Alarcon, Zonia ; Arévalo, Adriana ; Cifuentes, Helly Casallas ; Estrada, Kelly ; Puerto, Gloria ; Herrera Sepúlveda, María T. ; Rodríguez, Helena ; Galindo, Marisol ; Ospina Ramírez, Martha Lucía</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>betacoronavirus</topic><topic>colombia</topic><topic>coronavirus infections</topic><topic>diagnostics</topic><topic>Original Research</topic><topic>serologic tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mercado, Marcela</creatorcontrib><creatorcontrib>Malagón-Rojas, Jeadran</creatorcontrib><creatorcontrib>Delgado, Gabriela</creatorcontrib><creatorcontrib>Rubio, Vivian Vanesa</creatorcontrib><creatorcontrib>Muñoz Galindo, Lida</creatorcontrib><creatorcontrib>Parra Barrera, Eliana L.</creatorcontrib><creatorcontrib>Gaviria, Paula</creatorcontrib><creatorcontrib>Zabaleta, Gabriela</creatorcontrib><creatorcontrib>Alarcon, Zonia</creatorcontrib><creatorcontrib>Arévalo, Adriana</creatorcontrib><creatorcontrib>Cifuentes, Helly Casallas</creatorcontrib><creatorcontrib>Estrada, Kelly</creatorcontrib><creatorcontrib>Puerto, Gloria</creatorcontrib><creatorcontrib>Herrera Sepúlveda, María T.</creatorcontrib><creatorcontrib>Rodríguez, Helena</creatorcontrib><creatorcontrib>Galindo, Marisol</creatorcontrib><creatorcontrib>Ospina Ramírez, Martha Lucía</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Revista panamericana de salud pública</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mercado, Marcela</au><au>Malagón-Rojas, Jeadran</au><au>Delgado, Gabriela</au><au>Rubio, Vivian Vanesa</au><au>Muñoz Galindo, Lida</au><au>Parra Barrera, Eliana L.</au><au>Gaviria, Paula</au><au>Zabaleta, Gabriela</au><au>Alarcon, Zonia</au><au>Arévalo, Adriana</au><au>Cifuentes, Helly Casallas</au><au>Estrada, Kelly</au><au>Puerto, Gloria</au><au>Herrera Sepúlveda, María T.</au><au>Rodríguez, Helena</au><au>Galindo, Marisol</au><au>Ospina Ramírez, Martha Lucía</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of nine serological rapid tests for the detection of SARS-CoV-2</atitle><jtitle>Revista panamericana de salud pública</jtitle><date>2020-12-14</date><risdate>2020</risdate><volume>44</volume><issue>149</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>1020-4989</issn><eissn>1680-5348</eissn><abstract>Objective.
To evaluate the operative capacity of nine serological rapid tests to detect the IgM/IgG antibodies response in serum from patients with SARS-CoV-2 in different clinical stages.
Methods.
A cross-sectional study of serological rapid tests was designed to compare the performance of the evaluated immunochromatographic tests for the diagnosis of SARS-CoV-2. A total of 293 samples was used, including negatives, asymptomatic, and symptomatic serum samples.
Results.
The sensitivity of the evaluated tests was low and moderate in the groups of asymptomatic serum samples and the group of serums coming from patients with less than 11 days since the onset of the symptoms. The specificity for the anti-SARS-CoV-2 antibodies tests ranged between 86.5%-99% for IgM and 86.5%-99.5% for IgG. The sensitivity and the likelihood ratio were different according to the study groups. The usefulness of these tests is restricted to symptomatic patients and their sensitivity is greater than 85% after 11 days from the appearance of symptoms.
Conclusions.
Serological tests are not an adequate strategy for the identification of asymptomatic and pre-symptomatic patients. Serological rapid tests for the detection of specific anti-SARS-CoV-2 antibodies can be used as a diagnostic aid, but diagnosis must be confirmed by RT-PCR. Rapid tests should be reserved for patients with symptoms lasting more than 11 days.</abstract><pub>Organización Panamericana de la Salud</pub><doi>10.26633/RPSP.2020.149</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1020-4989 |
ispartof | Revista panamericana de salud pública, 2020-12, Vol.44 (149), p.1-9 |
issn | 1020-4989 1680-5348 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_470c6cc78890490a92100f3454bd3185 |
source | PubMed Central(OpenAccess) |
subjects | betacoronavirus colombia coronavirus infections diagnostics Original Research serologic tests |
title | Evaluation of nine serological rapid tests for the detection of SARS-CoV-2 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T06%3A35%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20nine%20serological%20rapid%20tests%20for%20the%20detection%20of%20SARS-CoV-2&rft.jtitle=Revista%20panamericana%20de%20salud%20p%C3%BAblica&rft.au=Mercado,%20Marcela&rft.date=2020-12-14&rft.volume=44&rft.issue=149&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=1020-4989&rft.eissn=1680-5348&rft_id=info:doi/10.26633/RPSP.2020.149&rft_dat=%3Cpubmedcentral_doaj_%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_7734239%3C/pubmedcentral_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |